Laura Emionite

Ospedale Policlinico San Martino — Italy

Medicine · Health Sciences

37h-index4.4kcitations141works6.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(45), Cancer, Hypoxia, and Metabolism(23), Adenosine and Purinergic Signaling(15), Cancer Treatment and Pharmacology(12), Metabolism, Diabetes, and Cancer(9)

Publications141 total

Increased [18F]DPA-714 Uptake in the Skeletal Muscle of SOD1G93A Mice: A New Potential of Translocator Protein 18 kDa Imaging in Amyotrophic Lateral Sclerosis
Biomolecules·2025· 1 citedOpen Access
A pH-sensitive closed-loop nanomachine to control hyperexcitability at the single neuron level
Nature Communications·2024· 11 citedOpen Access
The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer
Journal of Experimental & Clinical Cancer Research·2024· 8 citedOpen Access
Mandatory role of endoplasmic reticulum and its pentose phosphate shunt in the myocardial defense mechanisms against the redox stress induced by anthracyclines
Molecular and Cellular Biochemistry·2023· 9 citedOpen Access
Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S3 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S2 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S3 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S2 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Data from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Data from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Figure S1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy
2023Open Access
Figure S2 from Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7
2023Open Access
SMovie S4 from Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Michele Cilli(21), Fabio Pastorino(16), Mirco Ponzoni(16), Cecilia Marini(14), Gianmario Sambuceti(14), Lizzia Raffaghello(11), Chiara Brignole(10), Anna Maria Orengo(9), Daniela Di Paolo(9), Patrizia Perri(9), Vito Pistoia(8), Monica Loi(8), Giovanna Bianchi(7), Ambra Buschiazzo(7), Silvia Ravera(7), Adriana Amaro(7), Ulrich Pfeffer(7), Silvia Bruno(7), Mirko Magnone(7), Selene Capitanio(6)